RESMETIROM
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.7M | 13,832 | 7,511 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 144 | 75.5% |
| Food and Beverage | $370,657 | 13,659 | 21.9% |
| Honoraria | $43,445 | 24 | 2.6% |
| Travel and Lodging | $1,651 | 5 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | Madrigal Pharmaceuticals | $1.3M | 0 |
Top Doctors Receiving Payments for RESMETIROM — Page 5
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , D.O | Internal Medicine | Washington, DC | $249.47 | 2 |
| , MD | Endocrinology, Diabetes & Metabolism | Ponce, PR | $249.41 | 3 |
| , M.D | Specialist | Brooklyn, NY | $247.38 | 5 |
| , M.D | Internal Medicine | Houston, TX | $245.92 | 4 |
| , MS, PA-C | Physician Assistant | Louisville, CO | $245.47 | 4 |
| , M.D | Gastroenterology | Miami Beach, FL | $240.95 | 4 |
| , MD | Gastroenterology | New Windsor, NY | $240.62 | 6 |
| , CRNP | Nurse Practitioner | Washington, PA | $240.18 | 12 |
| , FNP-BC | Family | Walnut Creek, CA | $239.89 | 2 |
| , M.D | Internal Medicine | Tacoma, WA | $238.77 | 2 |
| , MD | Hepatology | Baytown, TX | $236.10 | 6 |
| , CRNP | Nurse Practitioner | Baltimore, MD | $236.02 | 3 |
| Iman Jomaa | Physician Assistant | Pasadena, CA | $234.42 | 9 |
| , M.D | Internal Medicine | Portland, ME | $233.63 | 2 |
| , D.O | Gastroenterology | Dallas, TX | $230.58 | 4 |
| , NP | Nurse Practitioner | Ogden, UT | $228.94 | 4 |
| , MD | Gastroenterology | Los Alamitos, CA | $227.94 | 6 |
| , M.D | Gastroenterology | Los Angeles, CA | $227.12 | 2 |
| , B.S | Student in an Organized Health Care Education/Training Program | Los Angeles, CA | $227.12 | 2 |
| , CRNP | Nurse Practitioner | Los Angeles, CA | $226.64 | 2 |
| , PA-C | Physician Assistant | Los Alamitos, CA | $226.38 | 8 |
| , M.D | Internal Medicine | Houston, TX | $226.13 | 2 |
| Nathaniel Ernstoff | Gastroenterology | Coral Springs, FL | $221.69 | 10 |
| , M.D | Internal Medicine | Dallas, TX | $221.52 | 5 |
| , M.D | Internal Medicine | New York, NY | $220.84 | 2 |
Manufacturing Companies
- Madrigal Pharmaceuticals $1.7M
Product Information
- Type Drug
- Total Payments $1.7M
- Total Doctors 7,511
- Transactions 13,832
About RESMETIROM
RESMETIROM is a drug associated with $1.7M in payments to 7,511 healthcare providers, recorded across 13,832 transactions in the CMS Open Payments database. The primary manufacturer is Madrigal Pharmaceuticals.
Payment data is available from 2024 to 2024. In 2024, $1.7M was paid across 13,832 transactions to 7,511 doctors.
The most common payment nature for RESMETIROM is "Unspecified" ($1.3M, 75.5% of total).
RESMETIROM is associated with 1 research study, including "A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)" ($1.3M).